| 摘要: |
| 目的 研究claudin-3和β-连环素(β-catenin)蛋白在卵巢交界性肿瘤(borderline ovarian tumors,BOTs)组织中的表达及临床病理意义。方法 采用免疫组织化学SP法检测claudin-3和β-catenin蛋白在69例BOTs组织中的表达,并与其在17例正常卵巢组织、31例卵巢上皮性良性肿瘤、39例卵巢上皮性恶性肿瘤组织中的表达进行比较。结果 BOTs组织中claudin-3蛋白的阳性表达率(59.4%,41/69)低于卵巢癌组织中的阳性表达率(89.7%,35/39),而高于良性肿瘤及正常卵巢组织中的表达率(22.6%,7/31;5.9%,1/17),差异均有统计学意义(P<0.01);正常卵巢组织与良性肿瘤相比,差异无统计学意义(P>0.05)。BOTs组织中β-catenin蛋白的阳性表达率(52.2%,36/69)低于卵巢癌组织中的阳性表达率(84.7%,33/39),而高于良性肿瘤及正常卵巢组织中的表达率(29.0%,9/31;11.8%,2/17),差异均有统计学意义(P<0.01或P<0.05)；而正常卵巢组织与良性肿瘤相比,差异无统计学意义(P>0.05)。Claudin-3和β-catenin蛋白的表达与BOTs患者的临床病理分期以及腹腔有无种植相关(P<0.05),而与组织学类型和患者年龄无关(P>0.05)。Claudin-3与β-catenin在BOTs组织中的表达呈正相关(r=0.439, P=0.000)。结论 Claudin-3与β-catenin在BOTs的发生、发展中可能起着协同作用,对其进行联合检测有助于BOTs的诊断和治疗。 |
| 关键词: 卵巢肿瘤 免疫组织化学 claudin-3 β-catenin |
| DOI：10.3724/SP.J.1008.2012.00449 |
| 投稿时间：2011-09-29修订日期：2012-03-19 |
| 基金项目:安徽省皖南医学院中青年科研项目(WK200828F). |
|
| Expression of claudin-3 and β-catenin in borderline ovarian tumors and its clinicopathological significance |
| WANG Xiang-ming1,GU Qian2,YU Dong-hong3,LIU Yin-hua1,LI Jia-jia1,ZHANG Fan1* |
(1. Department of Pathology, Yijishan Hospital, Wannan Medical College, Wuhu241001, Anhui, China
2. Department of Pathology, Wannan Medical College, Wuhu241000, Anhui, China
3. Department of Pathology, Bengbu Medical College, Bengbu233030, Anhui, China
*Corresponding author.) |
| Abstract: |
| Objective To investigate the expression of claudin-3 and β-catenin in borderline ovarian tumors (BOTs) and its clinicopathological significance. Methods We examined the expressions of claudin-3 and β-catenin and their relationship with the clinicopathological features in 17 normal ovarian tissues, 31 epithelial benign ovarian tumors, 39 epithelial malignant ovarian tumors and 69 BOTs by SP immunohistochemistry method. Results The positive expression rate of claudin-3 protein in BOTs (59.4%, 41/69) was significantly lower than that in the malignant ovarian tumors (89.7%, 35/39), and higher than that in normal ovaries (5.9%, 1/17) and benign ovarian tumors (22.6%, 7/31)(P<0.01); the expressions were not significantly different between the normal ovaries and benign ovarian tumors (P>0.05). The positive expression rate of β-catenin protein in BOTs (52.2%, 36/39) was significantly lower than that in the malignant ovarian tumors (84.7%, 33/39), and higher than that in normal ovaries (11.8%, 2/17) and benign ovarian tumors (29.0%, 9/31; P<0.01 or P<0.05); the expressions were not significantly different between the normal ovaries and benign ovarian tumors (P>0.05).The expression of claudin-3 and β-catenin was correlated with the clinciopathological stage and intraperitoneal metastases (P<0.05), but not with the histological type or age of BOTs patients (P>0.05). Expression of claudin-3 and β-catenin was positively correlated in BOTs (r=0.439, P=0.000). Conclusion Claudin-3 and β-catenin may play a synergistic role in the oncogenesis and progression of BOTs. Simutaneous detection of claudin-3 and β-catenin is valuable for diagnosis and treatment of BOTs. |
| Key words: ovarian neoplasms immunohistochemistry claudin-3 β-catenin |
